The Modular Training for the Bioprocess Industries (MBI) programme pioneered by UCL Biochemical Engineering is a series of intensive short modules designed for professionals in the bioprocessing industry. The MBI Programme has a long history of equipping the bioprocessing industry's workforce with up-to-date skills and knowledge of process options in order to rapidly develop validatable, efficient and robust processes.
The Global Biotech Summit is the UAE's most important integrated platform for strategic innovation, investment, and breakthrough collaboration in biotechnology and life sciences, bringing together global and regional leaders, visionary scientists, investors, policymakers, and innovators.
Join life sciences experts and practitioners across health, academia, and government at Westminster Insight's inaugural Life Sciences Forum on Wednesday 10th June in London.
Don't miss the opportunity to hear our fantastic array of cross-cutting experts share insights into trials, new HDR service, AI and tech innovation, plus funding and investment opportunities.
Take away key learnings from our unique combination of Government insights, innovative perspectives, focussed case studies, and panel sessions.
Set for 10 June 2026 at the Magdalen Centre in the Oxford Science Park, the Creative Disruption Forum on the Future of Neuro Therapeutics and CNS Health Innovations is an exclusive, interview-led event. Hosted by industry veterans Prof Tony Sedgwick and Graham Combe, it brings together an elite lineup of life sciences executives, CXOs, and R&D directors. The forum dives deep into breakthrough strategies for neurodegenerative diseases and central nervous system (CNS) health. Moving past standard panels, it features direct thought-leader interviews and interactive afternoon workshops designed to spark collaboration, build trusted peer networks, and accelerate commercialization.
SS&C Intralinks and Capital for Cures host an evening in London on 10 June 2026 focused on royalty financing. Globally a $20B+ annual market, royalty financing allows biotech and pharma companies to raise capital by selling a share of future product revenues, without diluting shareholders or taking on traditional debt. The mechanism has become a core part of the US life sciences funding stack, while European biotechs remain underserved and most deal flow continues to concentrate in North America. The evening brings together biotech executives, pharma BD teams, family offices, and specialist investors actively deploying into European royalty deals, featuring a moderated panel followed by extended networking.
Building on last year’s event, which attracted more than 4,000 attendees across 25+ venues and 200+ sessions, CWOW 2026 will convene investors, entrepreneurs, academics, policymakers, operators, the wider biotech/techbio community and residents alike, to explore the ecosystems and engage directly with the participants and ideas driving innovation.
